Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    nCT03798106
Previous Study | Return to List | Next Study

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03798106
Recruitment Status : Recruiting
First Posted : January 9, 2019
Last Update Posted : April 22, 2021
Sponsor:
Information provided by (Responsible Party):
Hyo Song Kim, Yonsei University

Brief Summary:
Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR-α and -β; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC) and advanced STS. For this orphan tumor, STS, PD-L1 targeting may be a promising strategy and favorable toxicity may warrant further combination.

Condition or disease Intervention/treatment Phase
Sarcoma Drug: Durvalumab, pazopanib Phase 2

Detailed Description:
Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR-α and -β; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC) and advanced STS. Pro-angiogenic factors suppress various immune functions whereas antiangiogenic agents have potential to modulate the tumor microenvironment and improve immunotherapy. An analysis of patients with RCC treated with pazopanib demonstrated that elevated expression of PD-L1 correlates with shorter PFS. Investigator also identified 43% of PD-L1 expression in STS and PD-L1 expression had worse overall survival (5-year survival rate: 48% in PD-L1 positive vs. 68% in PD-L1 negative, p=0.015). In detail, PD-L1 expression was reported 52.6% in synovial sarcoma, 37.6% in rhabdomyosarcoma, and 100% in epithelioid sarcoma. For this orphan tumor, STS, PD-L1 targeting may be a promising strategy and favorable toxicity may warrant further combination.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Actual Study Start Date : April 10, 2019
Estimated Primary Completion Date : August 10, 2022
Estimated Study Completion Date : August 10, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: durvalumab+pazopanib
Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
Drug: Durvalumab, pazopanib
Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks




Primary Outcome Measures :
  1. progression free rate [ Time Frame: 12 weeks ]
    antitumor efficacy of durvalumab and pazopanib



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed STS progression to 1 or 2 prior chemotherapy
  2. Age > 18 years at time of study entry.
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  4. Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1
  5. Body weight >30kg
  6. Adequate laboratory findings
  7. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.
  8. Patient is willing and able to comply with the protocol for the duration of the study
  9. Must have a life expectancy of at least 12 weeks
  10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  11. Patients with evidence of portal hypertension (including splenomegaly detected radiographically) or any prior history of variceal bleeding must have had endoscopic evaluation within the 3 months immediately prior to enrollment, and the findings do not represent a high bleeding risk.

Exclusion Criteria:

  1. More than 4 prior cytotoxic regimens
  2. Participation in another clinical study with an investigational product during the last 2 weeks
  3. Receipt of the last dose of anticancer therapy 14 days prior to the first dose of study drug
  4. Any previous treatment with a PD1 or PD-L1 inhibitor (including durvalumab) and/or pazopanib
  5. Mean QT interval corrected for heart rate (QTc) >480 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's Correction
  6. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
  7. Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment within 2 weeks prior to entering the study. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
  8. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug
  9. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.
  10. History of allogenic organ transplantation.
  11. Active or prior documented autoimmune or inflammatory disorders
  12. Uncontrolled intercurrent illness
  13. History of active infection
  14. History of another primary malignancy
  15. History of leptomeningeal carcinomatosis who are neurologically unstable or have required active treatment
  16. Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational product(IP).
  17. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose.
  18. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
  19. No history of any of the following in the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease class III or IV congestive heart failure, as defined by the New York Heart Association), thromboembolic events

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03798106


Contacts
Layout table for location contacts
Contact: Hyo Song Kim, Ph.D 82-2-2228-8124 hyosong77@yuhs.ac

Locations
Layout table for location information
Korea, Republic of
Severance Hospital, Yonsei University Health System Recruiting
Seoul, Korea, Republic of, 03722
Contact: Hyo Song Kim    82-2-2228-8124    hyosong77@yuhs.ac   
Sponsors and Collaborators
Yonsei University
Layout table for additonal information
Responsible Party: Hyo Song Kim, professor, Yonsei University
ClinicalTrials.gov Identifier: NCT03798106    
Other Study ID Numbers: 4-2018-0743
First Posted: January 9, 2019    Key Record Dates
Last Update Posted: April 22, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Durvalumab
Antineoplastic Agents, Immunological
Antineoplastic Agents